Synthetic lethality is fundamentally linked to the DNA damage response as it often functions by inhibiting genes that disrupt the DNA damage response (DDR) signaling pathway [1], [2]. Furthermore, DDR pathways serve as the primary driver for the majority of synthetic lethality clinical trials in solid tumors [3], [4], though some trials specifically target pathways outside of the DNA damage response [5].